Impax Laboratories (IPXL) Awarded Positive Decision in LCI Zomig Suit - RBC
Get Alerts IPXL Hot Sheet
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 2 | New: 35
Join SI Premium – FREE
RBC Capital analyst Randall Stanicky notes a Delaware district court rendered a decision in Impax Laboratories' (NASDAQ: IPXL) favor related to its suit against LCI for its generic Zomig (Zolmitriptan) 5mg Nasal Spray filing.
Stanicky said this is positive for the company and adds visibility around the product. It follows positive news earlier in the week that Paul Bisaro is the new CEO/President.
The firm maintained an Sector Perform rating and price target of $10.00
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $12.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Veradigm Inc (MDRX) to Hold
- Guggenheim Starts Perficient (PRFT) at Neutral
- Guggenheim Starts Telus International (TIXT) at Neutral
Create E-mail Alert Related Categories
Analyst Comments, FDA, LitigationRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!